Northwest Biotherapeutics (OTCMKTS:NWBO - Get Free Report) posted its quarterly earnings results on Monday, March 31st. The biotechnology company reported ($0.02) EPS for the quarter, Zacks reports. The firm had revenue of $0.23 million during the quarter.
Northwest Biotherapeutics Stock Down 1.2 %
OTCMKTS NWBO traded down $0.00 during trading hours on Monday, hitting $0.21. 4,994,442 shares of the company were exchanged, compared to its average volume of 3,223,902. The company has a 50 day moving average of $0.25 and a two-hundred day moving average of $0.27. The firm has a market cap of $288.44 million, a price-to-earnings ratio of -2.59 and a beta of -0.67. Northwest Biotherapeutics has a 52-week low of $0.17 and a 52-week high of $0.57.
About Northwest Biotherapeutics
(
Get Free Report)
Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.
Further Reading
Before you consider Northwest Biotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Northwest Biotherapeutics wasn't on the list.
While Northwest Biotherapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
